Low-density lipoprotein receptor genotype-dependent response to cholesterol lowering by combined pravastatin and cholestyramine in familial hypercholesterolemia.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  American Journal of Cardiology

• Publication date

  1998-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0002-9149(98)00230-6PMID 9671018
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical characteristics of double heterozygotes with familial hypercholesterolemia and cholesteryl ester transfer protein deficiency.

  1997cited by this paper
• Is responsiveness to lovastatin in familial hypercholesterolaemia heterozygotes influenced by the specific mutation in the low‐density lipoprotein receptor gene?

  1995cited by this paper
• Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of HDL-cholesterol in a general Japanese population

  1994cited by this paper
• National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II).

  1994cited by this paper
• Influence of specific mutations at the LDL-receptor gene locus on the response to simvastatin therapy in Afrikaner patients with heterozygous familial hypercholesterolaemia.

  1993cited by this paper
• Reduction of lipoprotein(a) by LDL-apheresis using a dextran sulfate cellulose column in patients with familial hypercholesterolemia.

  1993cited by this paper
• Genetic Determinants of Responsiveness to the HMG‐CoA Reductase Inhibitor Fluvastatin in Patients With Molecularly Defined Heterozygous Familial Hypercholesterolemia

  1993cited by this paper
• Serum apolipoproteins in heterozygous familial hypercholesterolemia.

  1992cited by this paper
• Molecular genetics of the LDL receptor gene in familial hypercholesterolemia

  1992cited by this paper
• Pravastatin in heterozygous familial hypercholesterolemia: low-density lipoprotein (LDL) cholesterol-lowering effect and LDL receptor activity on skin fibroblastS.

  1991cited by this paper
• Treatment of familial hypercholesterolaemia: a controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels

  1990cited by this paper
• Identification of a point mutation in growth factor repeat C of the low density lipoprotein-receptor gene in a patient with homozygous familial hypercholesterolemia that affects ligand binding and intracellular movement of receptors.

  1989cited by this paper
• Development of coronary heart disease in familial hypercholesterolemia.

  1989cited by this paper
• New Variant of Low Density Lipoprotein Receptor Gene: FH×Tonami

  1988cited by this paper
• Effects of CS-514 on serum lipoprotein lipid and apolipoprotein levels in patients with familial hypercholesterolemia.

  1987cited by this paper
• [Treatment of familial hypercholesterolemia].

  1987cited by this paper
• Causes of death in patients with familial hypercholesterolemia.

  1986cited by this paper
• Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine.

  1983cited by this paper
• Effects of ML-236b (compactin) on sterol synthesis and low density lipoprotein receptor activities in fibroblasts of patients with homozygous familial hypercholesterolemia.

  1981cited by this paper
• Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

  1972cited by this paper

• The Power to Predict: Does LDLR mutation status determine statin responsiveness?

  2022cites this paper
• Influence of the LDL-receptor genotype on statin response in heterozygous familial hypercholesterolemia: insights from the Canadian FH Registry.

  2021cites this paper
• Pharmacogenomics Variability of Lipid-Lowering Therapies in Familial Hypercholesterolemia

  2021cites this paper
• Management of patients with familial hypercholesterolaemia

  2015cites this paper
• Pharmacogenomics of lipid-lowering therapies.

  2013cites this paper
• Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia.

  2012cites this paper
• Pharmacogenomics of Cardiovascular Drugs

  2012cites this paper
• Familial hypercholesterolemia and triglyceride metabolism.

  2011cites this paper
• Familial hypercholesterolemia in childhood: diagnostics, therapeutical options and risk stratification

  2009cites this paper
• Pharmacogenetics of HMG-CoA Reductase Inhibitors: Optimizing the Prevention of Coronary Heart Disease

  2009cites this paper
• Genetics and therapy of familial hypercholesterolemia de

  2007cites this paper
• Effect of ezetimibe coadministered with statins in genotype-confirmed heterozygous FH patients.

  2007cites this paper
• Complex genetics of monogenic familial hypercholesterolemia

  2006cites this paper
• Low-Density Lipoprotein Receptor Genotype and Response to Pravastatin in Children With Familial Hypercholesterolemia: Substudy of an Intima-Media Thickness Trial

  2005cites this paper
• Familial hypercholesterolemia and response to statin therapy according to LDLR genetic background

  2005cites this paper
• Hypolipidemic treatment of heterozygous familial hypercholesterolemia: a lifelong challenge

  2004cites this paper
• Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management.

  2004cites this paper
• Pharmacogenetics of lipid diseases

  2004cites this paper
• Effect of pretreatment vitamin D levels on in vivo effects of atorvastatin on bone metabolism in patients with heterozygous familial hypercholesterolemia.

  2003cites this paper
• The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.

  2002cites this paper
• DNA Testing for Familial Hypercholesterolemia

  2002cites this paper
• DNA testing for familial hypercholesterolemia: improving disease recognition and patient care.

  2002cites this paper
• [Familial hypercholesterolemia].

  2001cites this paper
• LDL‐receptor gene mutations and the hypocholesterolemic response to statin therapy

  2001cites this paper
• Determinants of Variable Response to Statin Treatment in Patients With Refractory Familial Hypercholesterolemia

  2001cites this paper
• Molecular Genetics and Clinical Features of Japanese Patients with Familial Hypercholesterolemia

  2000cites this paper
• Transjugular approach to concurrent mitral‐aortic and mitral‐tricuspid balloon valvuloplasty

  2000cites this paper
• Long-term (14 years) effect of LDL apheresis on obstructive changes in aortocoronary saphenous-vein bypass grafts in a case of heterozygous familial hypercholesterolemia with the LDL receptor proline664 to leucine mutation.

  2000cites this paper
• Genetic testing, screening, and counseling issues in cardiovascular disease.

  1999cites this paper
• Treatment of dyslipidemia: Genetic interactions with diet and drug therapy

  1999cites this paper
• The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia.

  1999cites this paper
• Definitive percutaneous treatment of Lutembacher's syndrome

  1999cites this paper